Wedbush reaffirmed their buy rating on shares of Lexicon Pharmaceuticals (NASDAQ:LXRX) in a research note issued to investors on Monday morning, TipRanks reports. Wedbush currently has a $10.00 target price on the biopharmaceutical company’s stock.

Other research analysts have also issued reports about the stock. Gabelli lowered shares of Lexicon Pharmaceuticals from a buy rating to a hold rating in a research note on Wednesday, December 11th. They noted that the move was a valuation call. ValuEngine lowered shares of Lexicon Pharmaceuticals from a sell rating to a strong sell rating in a research note on Tuesday, March 3rd. G.Research lowered shares of Lexicon Pharmaceuticals from a buy rating to a hold rating in a research note on Wednesday, December 11th. Zacks Investment Research lowered shares of Lexicon Pharmaceuticals from a buy rating to a hold rating in a research note on Thursday, March 12th. Finally, BidaskClub lowered shares of Lexicon Pharmaceuticals from a hold rating to a sell rating in a research note on Friday, March 6th. Two equities research analysts have rated the stock with a sell rating, six have issued a hold rating and one has assigned a buy rating to the company. Lexicon Pharmaceuticals presently has a consensus rating of Hold and a consensus target price of $4.70.

Shares of Lexicon Pharmaceuticals stock opened at $1.91 on Monday. The company has a debt-to-equity ratio of 2.00, a current ratio of 5.17 and a quick ratio of 5.10. The company has a 50-day moving average of $2.61 and a 200 day moving average of $3.39. The firm has a market cap of $215.01 million, a price-to-earnings ratio of 1.84 and a beta of 1.12. Lexicon Pharmaceuticals has a 1 year low of $1.13 and a 1 year high of $7.27.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last issued its quarterly earnings results on Thursday, March 12th. The biopharmaceutical company reported ($0.48) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.77) by $0.29. The company had revenue of $8.73 million during the quarter, compared to analyst estimates of $10.59 million. Lexicon Pharmaceuticals had a net margin of 40.40% and a return on equity of 303.98%. On average, equities analysts anticipate that Lexicon Pharmaceuticals will post -2.18 EPS for the current year.

Large investors have recently added to or reduced their stakes in the business. Meeder Asset Management Inc. increased its stake in Lexicon Pharmaceuticals by 755.6% during the 4th quarter. Meeder Asset Management Inc. now owns 9,857 shares of the biopharmaceutical company’s stock valued at $40,000 after purchasing an additional 8,705 shares in the last quarter. Commonwealth Equity Services LLC increased its stake in Lexicon Pharmaceuticals by 40.5% during the 3rd quarter. Commonwealth Equity Services LLC now owns 16,461 shares of the biopharmaceutical company’s stock valued at $49,000 after purchasing an additional 4,746 shares in the last quarter. Raymond James Financial Services Advisors Inc. bought a new stake in Lexicon Pharmaceuticals during the 4th quarter valued at about $60,000. Norges Bank bought a new stake in Lexicon Pharmaceuticals during the 4th quarter valued at about $89,000. Finally, Credit Suisse AG increased its stake in Lexicon Pharmaceuticals by 22.2% during the 4th quarter. Credit Suisse AG now owns 32,202 shares of the biopharmaceutical company’s stock valued at $134,000 after purchasing an additional 5,853 shares in the last quarter.

About Lexicon Pharmaceuticals

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products. The company offers XERMELO, an orally-delivered small molecule drug candidate for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog therapy in adults.

Recommended Story: Why are trading ranges significant?

Analyst Recommendations for Lexicon Pharmaceuticals (NASDAQ:LXRX)

Receive News & Ratings for Lexicon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.